P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

January 2013

Features

Deaths From Contaminated Methylprednisolone Highlight Failures of Compounding Pharmacies

Less Hospital Access to Outside Vendors and More Visits From State Pharmacy Boards

To avoid more fatalities and cases of fungal meningitis, as occurred from contaminated steroid products made at the New England Compounding Center, hospitals and their pharmacy directors must stay abreast of future changes in state and federal laws regarding compounding.
Stephen Barlas

Current Diagnosis and Treatment of Anxiety Disorders

The authors review the challenges in diagnosis; the roles of stress, neurotransmitters, and biological factors; cognitive–behavior therapy; and pharmacological and nonpharmacological strategies in patients with anxiety.
Alexander Bystritsky, MD, PhD; Sahib S. Khalsa, MD, PhD; Michael E. Cameron, PhD; and Jason Schiffman, MD, MA, MBA

Novel Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip or Knee Replacement

An Update on Rivaroxaban (Xarelto)

Novel anticoagulants represent promising alternatives to the traditional anticoagulants for VTE prophylaxis following hip and knee replacement surgery. Preliminary analyses for rivaroxaban suggest that it may be cost-effective and cost-saving in these patients.
Zachary Stacy, PharmD, BCPS

Meeting Highlights

American Heart Association Scientific Sessions 2012
American Association for the Study of Liver Disease
American College of Rheumatology/Association of Rheumatology Health Professionals

Topics include serelaxin, aspirin alone, and aspirin combinations for cardiovascular disease; sovaprevir and pegylated interferon/ribavirin combinations for hepatitis C; apremilast and ustekinumab for psoriatic arthritis; and a newly approved drug, tofacitinib, for rheumatoid arthritis.
Walter Alexander

Departments

Medication Errors

Oral Syringes: Making Better Use of a Crucial And Economical Risk-Reduction Strategy

Using a parenteral syringe to prepare or give oral or enteral liquids can be deadly.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Pharmacies Cannot Directly Bill Medicare For Compounded Drugs Sent to Physicians

Pharmacies can no longer bill Medicare directly for compounded drugs that they supply to physicians.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Tofacitinib (Xeljanz) for rheumatoid arthritis, perampanel (Fycompa) for partial-onset seizures, and teriflunomide (Aubagio) for relapsing multiple sclerosis
Marvin M. Goldenberg, PhD, RPh, MS

Drug Forecast

Abiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer

Abiraterone (Zytiga) for castration-resistant prostate cancer
Tamara Goldberg, PharmD, BCPS; and Evangelina Berrios-Colon, PharmD, MPH, BCPS, CACP